Skip to Main Content

Paper Details

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.
0
2023
-, ATR, Acalabrutinib, BTK, Bruton tyrosine kinase, CLL, CLL cells, Ceralasertib, DLTs, Patients, R, TEAEs, acalabrutinib, and, anemia, ataxia telangiectasia and Rad-3-, ataxia telangiectasia and Rad-3-related protein, ceralasertib, chronic lymphocytic leukemia, defective CLL cells, in, inhibitor, patients, thrombocytopenia, tyrosine
Author NameAffiliation
Amanda G PaulovichClinical Research Division, Fred Hutchinson Cancer Center
Jeffrey R WhiteakerClinical Research Division, Fred Hutchinson Cancer Center
  • 1 - 2

Datasets

Release 1.2